Skip to main content
Fig. 11 | BMC Cancer

Fig. 11

From: Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma

Fig. 11

Testing of prognostic value of risk signature. A ROC analysis was employed to estimate the prediction value of the prognostic signature in the ICGC-LIRI-JP cohort. B-D Areas under curves (AUCs) of the risk scores for predicting 1-, 2-, and 3-year overall survival time with other clinical characteristics in the ICGC-LIRI-JP cohort. E Nomogram was assembled by stage and risk signature for predicting survival of HCC patients from ICGC-LIRI-JP cohort. F 1-, 2-, and 3-year nomogram calibration curves in the ICGC-LIRI-JP cohort. G ROC analysis was employed to estimate the prediction value of the prognostic nomogram in the TCGA-LIHC project

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us